These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. [Outlook for the future in the treatment of diabetic retinopathy]. Vialettes B; Silvestre-Aillaud P; Atlan-Gepner C Diabete Metab; 1994; 20(2 Pt 2):229-34. PubMed ID: 7528151 [TBL] [Abstract][Full Text] [Related]
26. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. Meyer-Schwickerath R; Pfeiffer A; Blum WF; Freyberger H; Klein M; Lösche C; Röllmann R; Schatz H J Clin Invest; 1993 Dec; 92(6):2620-5. PubMed ID: 7504689 [TBL] [Abstract][Full Text] [Related]
27. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694 [TBL] [Abstract][Full Text] [Related]
28. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade. Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809 [TBL] [Abstract][Full Text] [Related]
29. Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study. McCombe M; Lightman S; Eckland DJ; Hamilton AM; Lightman SL Eye (Lond); 1991; 5 ( Pt 5)():569-75. PubMed ID: 1686591 [TBL] [Abstract][Full Text] [Related]
30. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420 [TBL] [Abstract][Full Text] [Related]
31. Growth hormone and somatostatin in glomerular injury. Baud L; Fouqueray B; Bellocq A; Doublier S; Dumoulin A J Nephrol; 1999; 12(1):18-23. PubMed ID: 10202998 [TBL] [Abstract][Full Text] [Related]
32. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852 [TBL] [Abstract][Full Text] [Related]
33. Insulin-like growth factor I (IGF-I) receptor/binding protein in human diabetic epiretinal membranes. Ulbig MW; Wolfensberger TJ; Hiscott P; Ationu A; Carter ND; Gregor ZJ Ger J Ophthalmol; 1995 Sep; 4(5):264-8. PubMed ID: 7496335 [TBL] [Abstract][Full Text] [Related]
34. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer]. Hofsli E Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977 [TBL] [Abstract][Full Text] [Related]
35. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Smith LE; Shen W; Perruzzi C; Soker S; Kinose F; Xu X; Robinson G; Driver S; Bischoff J; Zhang B; Schaeffer JM; Senger DR Nat Med; 1999 Dec; 5(12):1390-5. PubMed ID: 10581081 [TBL] [Abstract][Full Text] [Related]
36. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Castellon R; Caballero S; Hamdi HK; Atilano SR; Aoki AM; Tarnuzzer RW; Kenney MC; Grant MB; Ljubimov AV Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2758-66. PubMed ID: 12147613 [TBL] [Abstract][Full Text] [Related]
37. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392 [TBL] [Abstract][Full Text] [Related]
38. Suppressed expression of tubedown-1 in retinal neovascularization of proliferative diabetic retinopathy. Gendron RL; Good WV; Adams LC; Paradis H Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):3000-7. PubMed ID: 11687548 [TBL] [Abstract][Full Text] [Related]
39. Therapeutic uses of somatostatin and its analogues: Current view and potential applications. Rai U; Thrimawithana TR; Valery C; Young SA Pharmacol Ther; 2015 Aug; 152():98-110. PubMed ID: 25956467 [TBL] [Abstract][Full Text] [Related]
40. Functional aspects of the somatostatinergic system in the retina and the potential therapeutic role of somatostatin in retinal disease. Casini G; Catalani E; Dal Monte M; Bagnoli P Histol Histopathol; 2005 Apr; 20(2):615-32. PubMed ID: 15736065 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]